Forwardvue Pharma, Inc.

Forwardvue Pharma, Inc. is focused on developing innovative therapies for retinal neovascular diseases using a unique drug delivery platform that enhances patient treatment options and outcomes. Founded in 2019 and headquartered in Mobile, US, Forwardvue Pharma, Inc. specializes in novel treatments for retinal diseases.

Alan Franklin serves as both the Founder and CEO. The company has completed one investment deal, raising seed funding in August 2020. Forwardvue Pharma specializes in a novel VEGF-independent drug delivery platform aimed at treating retinal neovascular diseases. The company's lead product is a long-acting ORAI1 blocker, designed to provide durable administration for up to 12 months, with a target dosing regimen of 1-2 intravitreal injections annually.

This innovative approach seeks to alleviate the treatment burden on patients suffering from conditions such as diabetic retinopathy and age-related macular degeneration (AMD). The primary end users of these products include ophthalmologists and patients experiencing retinal diseases, with the company's focus on markets across North America and Europe, where the need for advanced therapeutic options is significant. Forwardvue Pharma aims to fulfill unmet medical needs by offering a product that not only blocks VEGF pathways but also addresses other mechanisms involved in retinal pathologies. Forwardvue Pharma's revenue model is centered around direct sales to healthcare providers and institutions specializing in ophthalmology.

The transactions typically occur through a structured framework involving healthcare systems and clinics that administer the company's products to patients. The pricing structure for the flagship ORAI1 blocker is established based on the value it provides in terms of reduced treatment frequency and improved patient outcomes. As a result, the company engages in partnership agreements with clinics to facilitate the distribution of its products. Revenue is generated primarily from the sales of these specialized treatments, aligning the company's financial incentives with the health outcomes of its clients and their patients.

Forwardvue Pharma is dedicated to expanding its product offerings and market presence. The company is currently developing new formulations of its ORAI1 blocker aimed at enhancing efficacy and patient adherence. Expanding into European markets is a key target, with plans to establish operations by the end of 2023. The recent seed funding raised in August 2020 will be allocated towards product development and marketing strategies to support market entry.